Literature DB >> 21715316

acDCs enhance human antigen-specific T-cell responses.

Emanuela Martinuzzi1, Georgia Afonso, Marie-Claude Gagnerault, Gaetano Naselli, Diana Mittag, Béhazine Combadière, Christian Boitard, Nathalie Chaput, Laurence Zitvogel, Leonard C Harrison, Roberto Mallone.   

Abstract

Detection of human Ag-specific T cells is limited by sensitivity and blood requirements. As dendritic cells (DCs) can potently stimulate T cells, we hypothesized that their induction in PBMCs in situ could link Ag processing and presentation to Ag-specific T-cell activation. To this end, unfractionated PBMCs (fresh or frozen) or whole blood were incubated for 48 hours with protein or peptide Ag together with different DC-activating agents to rapidly and sequentially induce, pulse, and mature DCs. DC activation was therefore lined up with Ag recognition by neighboring T cells, thus telescoping the sequential steps of T-cell activation. Efficient processing of protein Ags made prior knowledge of epitopes and HLA restrictions dispensable. While reducing stimulation time, manipulation and blood requirements, in situ DC induction specifically amplified Ag-specific T-cell responses (cytokine secretion, proliferation, CD137/CD154 up-regulation, and binding of peptide-HLA multimers). IL-1β, although released by DCs, was also secreted in an Ag-specific fashion, thus providing an indirect biomarker of T-cell responses. These accelerated cocultured DC (acDC) assays offered a sensitive means with which to evaluate T-cell responses to viral and melanoma Ag vaccination, and may therefore find application for immune monitoring in viral, tumor, autoimmune, and transplantation settings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715316     DOI: 10.1182/blood-2010-12-326231

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.

Authors:  Adriaan H C de Jongste; Marieke T de Graaf; Emanuela Martinuzzi; Patricia D M van den Broek; Jaco Kraan; Cor H J Lamers; Roberto Mallone; Jan W Gratama; Peter A E Sillevis Smitt
Journal:  Neuro Oncol       Date:  2012-05-15       Impact factor: 12.300

Review 2.  Pathogenic and regulatory T cells in type 1 diabetes: losing self-control, restoring it, and how to take the temperature.

Authors:  Slobodan Culina; Roberto Mallone
Journal:  Curr Diab Rep       Date:  2011-10       Impact factor: 4.810

3.  Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Authors:  Michelle Rosenzwajg; Guillaume Churlaud; Roberto Mallone; Adrien Six; Nicolas Dérian; Wahiba Chaara; Roberta Lorenzon; S Alice Long; Jane H Buckner; Georgia Afonso; Hang-Phuong Pham; Agnès Hartemann; Aixin Yu; Alberto Pugliese; Thomas R Malek; David Klatzmann
Journal:  J Autoimmun       Date:  2015-01-26       Impact factor: 7.094

4.  The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.

Authors:  Alice Gutjahr; Laura Papagno; Francesco Nicoli; Tomohiro Kanuma; Nozomi Kuse; Mariela Pires Cabral-Piccin; Nicolas Rochereau; Emma Gostick; Thierry Lioux; Eric Perouzel; David A Price; Masafumi Takiguchi; Bernard Verrier; Takuya Yamamoto; Stéphane Paul; Victor Appay
Journal:  JCI Insight       Date:  2019-04-04

5.  Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors.

Authors:  Slobodan Culina; Ana Ines Lalanne; Georgia Afonso; Karen Cerosaletti; Sheena Pinto; Guido Sebastiani; Klaudia Kuranda; Laura Nigi; Anne Eugster; Thomas Østerbye; Alicia Maugein; James E McLaren; Kristin Ladell; Etienne Larger; Jean-Paul Beressi; Anna Lissina; Victor Appay; Howard W Davidson; Søren Buus; David A Price; Matthias Kuhn; Ezio Bonifacio; Manuela Battaglia; Sophie Caillat-Zucman; Francesco Dotta; Raphael Scharfmann; Bruno Kyewski; Roberto Mallone
Journal:  Sci Immunol       Date:  2018-02-02

6.  T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia.

Authors:  Tina Rubic-Schneider; Masataka Kuwana; Brigitte Christen; Manuela Aßenmacher; Otmar Hainzl; Frank Zimmermann; Robert Fischer; Vera Koppenburg; Salah-Dine Chibout; Timothy M Wright; Andreas Seidl; Michael Kammüller
Journal:  Blood Adv       Date:  2017-02-09

7.  Priming of Qualitatively Superior Human Effector CD8+ T Cells Using TLR8 Ligand Combined with FLT3 Ligand.

Authors:  Anna Lissina; Olivia Briceño; Georgia Afonso; Martin Larsen; Emma Gostick; David A Price; Roberto Mallone; Victor Appay
Journal:  J Immunol       Date:  2015-11-25       Impact factor: 5.422

8.  HLA-E-restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities.

Authors:  Hongbing Yang; Margarida Rei; Simon Brackenridge; Elena Brenna; Hong Sun; Shaheed Abdulhaqq; Michael K P Liu; Weiwei Ma; Prathiba Kurupati; Xiaoning Xu; Vincenzo Cerundolo; Edward Jenkins; Simon J Davis; Jonah B Sacha; Klaus Früh; Louis J Picker; Persephone Borrow; Geraldine M Gillespie; Andrew J McMichael
Journal:  Sci Immunol       Date:  2021-03-25

9.  Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics.

Authors:  Mathias Wilhelm; Daniel P Zolg; Michael Graber; Siegfried Gessulat; Tobias Schmidt; Karsten Schnatbaum; Celina Schwencke-Westphal; Philipp Seifert; Niklas de Andrade Krätzig; Johannes Zerweck; Tobias Knaute; Eva Bräunlein; Patroklos Samaras; Ludwig Lautenbacher; Susan Klaeger; Holger Wenschuh; Roland Rad; Bernard Delanghe; Andreas Huhmer; Steven A Carr; Karl R Clauser; Angela M Krackhardt; Ulf Reimer; Bernhard Kuster
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

10.  Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.

Authors:  Klaudia Kuranda; Priscilla Jean-Alphonse; Christian Leborgne; Romain Hardet; Fanny Collaud; Solenne Marmier; Helena Costa Verdera; Giuseppe Ronzitti; Philippe Veron; Federico Mingozzi
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.